In MYC-driven MBs, PI3K/AKT/mTOR signaling is also altered, with preclinical evidence that these inhibitors can target MB metastases and decrease growth in vitro and in vivo, with synergistic effects combined with BET inhibition [64,103] or HDAC inhibitors [104,105,106]. Here, MYC is linked to Mobius syndrome.